BACKGROUND: Clinical-pathological Alzheimer's disease (AD) subtypes may help distill heterogeneity in patient presentation. To date, no studies have utilized neuropsychological and biological markers to identify preclinical subtypes with longitudinal stability. OBJECTIVE: The objective of this study was to empirically derive AD endophenotypes using a combination of cognitive and biological markers. METHODS: Hierarchical cluster analysis grouped dementia-free older adults using memory, executive and language abilities, and cerebrospinal fluid amyloid-β and phosphorylated tau. Brain volume differences, neuropsychological trajectory, and progression to dementia were compared, controlling for age, gender, education, and apolipoprotein E4 (ApoE4). RESULTS: Subgroups included asymptomatic-normal (n = 653) with unimpaired cognition and subthreshold biomarkers, typical AD (TAD; n = 191) showing marked memory decline, high ApoE4 rates and abnormal biomarkers, and atypical AD (AAD; n = 132) with widespread cognitive decline, intermediate biomarker levels, older age, less education and more white matter lesions. Cognitive profiles showed longitudinal stability with corresponding patterns of cortical atrophy, despite nearly identical rates of progression to AD dementia. CONCLUSION: Two clinical-pathological AD subtypes are identified with potential implications for preventative efforts.
BACKGROUND: Clinical-pathological Alzheimer's disease (AD) subtypes may help distill heterogeneity in patient presentation. To date, no studies have utilized neuropsychological and biological markers to identify preclinical subtypes with longitudinal stability. OBJECTIVE: The objective of this study was to empirically derive AD endophenotypes using a combination of cognitive and biological markers. METHODS: Hierarchical cluster analysis grouped dementia-free older adults using memory, executive and language abilities, and cerebrospinal fluid amyloid-β and phosphorylated tau. Brain volume differences, neuropsychological trajectory, and progression to dementia were compared, controlling for age, gender, education, and apolipoprotein E4 (ApoE4). RESULTS: Subgroups included asymptomatic-normal (n = 653) with unimpaired cognition and subthreshold biomarkers, typical AD (TAD; n = 191) showing marked memory decline, high ApoE4 rates and abnormal biomarkers, and atypical AD (AAD; n = 132) with widespread cognitive decline, intermediate biomarker levels, older age, less education and more white matter lesions. Cognitive profiles showed longitudinal stability with corresponding patterns of cortical atrophy, despite nearly identical rates of progression to AD dementia. CONCLUSION: Two clinical-pathological AD subtypes are identified with potential implications for preventative efforts.
Authors: Sheila Crean; Alex Ward; Catherine J Mercaldi; Jenna M Collins; Michael N Cook; Nicole L Baker; H Michael Arrighi Journal: Dement Geriatr Cogn Disord Date: 2010-12-01 Impact factor: 2.959
Authors: Lisa Delano-Wood; Mark W Bondi; Joshua Sacco; Norm Abeles; Amy J Jak; David J Libon; Andrea Bozoki Journal: J Int Neuropsychol Soc Date: 2009-11 Impact factor: 2.892
Authors: Yen Ying Lim; Simon M Laws; Victor L Villemagne; Robert H Pietrzak; Tenielle Porter; David Ames; Christopher Fowler; Stephanie Rainey-Smith; Peter J Snyder; Ralph N Martins; Olivier Salvado; Pierrick Bourgeat; Christopher C Rowe; Colin L Masters; Paul Maruff Journal: Neurology Date: 2016-03-30 Impact factor: 9.910
Authors: Emily C Edmonds; Joel Eppig; Mark W Bondi; Kelly M Leyden; Bailey Goodwin; Lisa Delano-Wood; Carrie R McDonald Journal: Neurology Date: 2016-10-19 Impact factor: 9.910
Authors: Christiane Reitz; Gyungah Jun; Adam Naj; Ruchita Rajbhandary; Badri Narayan Vardarajan; Li-San Wang; Otto Valladares; Chiao-Feng Lin; Eric B Larson; Neill R Graff-Radford; Denis Evans; Philip L De Jager; Paul K Crane; Joseph D Buxbaum; Jill R Murrell; Towfique Raj; Nilufer Ertekin-Taner; Mark Logue; Clinton T Baldwin; Robert C Green; Lisa L Barnes; Laura B Cantwell; M Daniele Fallin; Rodney C P Go; Patrick Griffith; Thomas O Obisesan; Jennifer J Manly; Kathryn L Lunetta; M Ilyas Kamboh; Oscar L Lopez; David A Bennett; Hugh Hendrie; Kathleen S Hall; Alison M Goate; Goldie S Byrd; Walter A Kukull; Tatiana M Foroud; Jonathan L Haines; Lindsay A Farrer; Margaret A Pericak-Vance; Gerard D Schellenberg; Richard Mayeux Journal: JAMA Date: 2013-04-10 Impact factor: 56.272
Authors: Daniel A Nation; Melanie D Sweeney; Axel Montagne; Abhay P Sagare; Lina M D'Orazio; Maricarmen Pachicano; Farshid Sepehrband; Amy R Nelson; David P Buennagel; Michael G Harrington; Tammie L S Benzinger; Anne M Fagan; John M Ringman; Lon S Schneider; John C Morris; Helena C Chui; Meng Law; Arthur W Toga; Berislav V Zlokovic Journal: Nat Med Date: 2019-01-14 Impact factor: 53.440
Authors: Kathryn N Devlin; Laura Brennan; Laura Saad; Tania Giovannetti; Roy H Hamilton; David A Wolk; Sharon X Xie; Dawn Mechanic-Hamilton Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472
Authors: Anna E Blanken; Jung Yun Jang; Jean K Ho; Emily C Edmonds; S Duke Han; Katherine J Bangen; Daniel A Nation Journal: JAMA Netw Open Date: 2020-03-02